Urogen Pharma LTD Schedule 13G passive stakes

The Toronto-Dominion Bank and TD Securities Inc. have filed a Schedule 13G, reporting beneficial ownership of 6.9% of UroGen Pharma Ltd.'s ordinary shares.

Paradigm BioCapital Advisors and associated entities have filed a Schedule 13G reporting a 3.5% beneficial ownership stake in UroGen Pharma Ltd.

The Toronto-Dominion Bank and TD Securities Inc. have filed a Schedule 13G, reporting beneficial ownership of 5.4% of UroGen Pharma Ltd.'s ordinary shares as of March 31, 2026.

BlackRock, Inc. has reported beneficial ownership of 5.2% of Urogen Pharma Ltd's common stock as of March 31, 2026.

The Toronto-Dominion Bank has reported a 4.9% beneficial ownership stake in UroGen Pharma Ltd., holding over 2.3 million ordinary shares.

Paradigm BioCapital Advisors LP and related entities have disclosed a 9.0% beneficial ownership stake in UroGen Pharma Ltd. as of September 30, 2025.

The Toronto-Dominion Bank has reported a 6.9% beneficial ownership stake in UroGen Pharma Ltd., holding 3,190,510 ordinary shares.

Cowen Financial Products LLC has reported a complete divestment of its beneficial ownership in UroGen Pharma Ltd. ordinary shares.

RA Capital Management and its affiliates have fully divested their beneficial ownership in Urogen Pharma Ltd., reporting 0% ownership as of June 30, 2025.

Paradigm BioCapital Advisors LP and its affiliates have disclosed a 5.0% beneficial ownership stake in UroGen Pharma Ltd., holding 2,332,066 ordinary shares.

Morgan Stanley has disclosed a 5.4% beneficial ownership stake in UroGen Pharma Ltd., holding 2,488,299 ordinary shares.

Soleus Capital Master Fund and related entities have disclosed a 4.7% beneficial ownership stake in UroGen Pharma Ltd., holding 2,185,000 ordinary shares.

Cowen Financial Products LLC has reported a 6.9% beneficial ownership stake in UroGen Pharma Ltd., holding 3,190,510 ordinary shares.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 5.0% in UROGEN PHARMA LTD's common stock as of June 30, 2025.

Soleus Capital Master Fund and its affiliated entities have disclosed a 5.0% beneficial ownership stake in UroGen Pharma Ltd., holding 2,325,000 ordinary shares.

Cowen Financial Products LLC has reported a passive 5.8% beneficial ownership stake in UroGen Pharma Ltd. as of June 9, 2025.

RA Capital Management, L.P. and its affiliates have filed an amended Schedule 13G, reporting a 7.0% beneficial ownership stake in Urogen Pharma Ltd. as of March 31, 2025.

Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has filed an amendment to their Schedule 13G, reporting a passive beneficial ownership of 2.77% in UroGen Pharma Ltd.'s Ordinary Shares as of March 31, 2025.

Menora Mivtachim Holdings Ltd. has filed an amendment to its Schedule 13G, disclosing a beneficial ownership of 4.99% in UroGen Pharma Ltd.'s ordinary shares as of March 11, 2025.

Adage Capital Management, L.P. and its principals, Robert Atchinson and Phillip Gross, have filed an amended Schedule 13G, confirming their continued beneficial ownership of 6.94% of UroGen Pharma Ltd.'s Ordinary Shares as of December 31, 2024.

Morgan Stanley has filed an amended Schedule 13G, reporting that its beneficial ownership in UroGen Pharma Ltd. has fallen to 1.8%, below the 5% reporting threshold.